Effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral rebound
Journal
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
Date Issued
2023-08-04
Author(s)
Chen, Guan-Jhou
Liu, Wen-Chun
Su, Yi-Ching
Abstract
Antiretroviral regimens containing a second-generation integrase strand-transfer inhibitor (INSTI) plus 2 nucleos(t)ide reverse-transcriptase inhibitors (NRTIs) are the recommended therapy for people with HIV (PWH) who are antiretroviral-naïve or on stable antiretroviral therapy (ART) with viral suppression. Real-world data on the virologic effectiveness of co-formulated bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) among PWH with virologic failure while receiving other ART remain sparse.
Subjects
Bictegravir; Dolutegravir; Genetic barrier; Nucleoside reverse-transcriptase inhibitor; Resistance-associated mutation; Salvage therapy; Virologic failure
SDGs
Type
journal article